

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

  
**CHINA ANIMAL HEALTHCARE**  
**CHINA ANIMAL HEALTHCARE LTD.**  
中國動物保健品有限公司\*  
*(Incorporated in Bermuda with limited liability)*  
*(Hong Kong Stock Code: 0940)*

**VOLUNTARY ANNOUNCEMENT**

**TRANSFER OF INTELLECTUAL PROPERTY RIGHTS OF NEW PRODUCTS**

This announcement is made by China Animal Healthcare Ltd. (“CAH” or the “Company” together with its subsidiaries, the “Group”) on a voluntary basis. The board of directors is pleased to announce that the Group has recently been transferred the intellectual property rights of new products.

On 16 September 2014, the Group entered into a Technology Transfer Agreement with Beijing Academy of Agriculture and Forestry Sciences in relation to the transfer of usage rights of:

- Combined Newcastle Disease and Avian Influenza (H9 Subtype) Vaccine, Inactivated (“Product A”);
- Newcastle Disease, Infectious Bronchitis and Egg Drop Syndrome Vaccine, Inactivated (Strain La Sota + Strain M41 + Strain HSH23) (“Product B”); and
- Newcastle Disease, Infectious Bronchitis, Egg Drop Syndrome and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain La Sota + Strain M41 + Strain HSH23 + Strain WD) (“Product C”).

Product A is suitable for all breeds and day-old chickens, which can prevent Newcastle Disease and H9 Subtype Avian Influenza. Product B is suitable for egg-laying hens, which can prevent Newcastle Disease, Infectious Bronchitis and Egg Drop Syndrome. Product C is suitable for egg-laying hens, which can prevent Newcastle Disease, Infectious Bronchitis, Egg Drop Syndrome and Avian Influenza (H9 Subtype).

The transfer of usage rights for these three vaccines will improve the range of poultry vaccines products of the Group and enhance its operational efficiency and market competitiveness.

None of the Directors or substantial shareholders of the Company has any interests, directly or indirectly, in the abovementioned transactions.

By Order of the Board  
**China Animal Healthcare Ltd.**  
**Wang Yangang**  
*Chairman, Executive Director  
and Chief Executive Officer*

Hong Kong, 22 September 2014

*As at the date of announcement, the executive Directors of the Company are Mr. Wang Yangang, Mr. Sun Jinguo and Mr. Li Jun; non-executive Directors are Mr. Alberto Riva, Dr. Ying Du and Mr. Goh Kay Seng Edwin; and the independent non-executive Directors are Mr. Cai Huiyi, Mr. Liang Hsien Tse Joseph and Mr. Liu Zhanmin.*

*\* For identification purpose only*